Director at Esperion (NASDAQ: ESPR) receives 79,873-share stock grant

Rhea-AI Filing Summary

Fischer Seth H. Z. reported acquisition or exercise transactions in this Form 4 filing.

Esperion Therapeutics director Seth H. Z. Fischer received an equity award of 79,873 shares of common stock as compensation. The grant carried a price of $0.00 per share and increased his directly held stake to 141,023 shares.

The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, meaning the shares are subject to a service-based vesting condition rather than being immediately unrestricted.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fischer Seth H. Z.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	79,873	$0.00	--

Holdings After Transaction: Common Stock — 141,023 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 79,873 shares Grant price: $0.00 per share Shares owned after grant: 141,023 shares +1 more

4 metrics

Shares granted 79,873 shares Director stock award on May 28, 2026

Grant price $0.00 per share Equity compensation, not open-market purchase

Shares owned after grant 141,023 shares Director’s direct holdings following the award

Vesting date condition Earlier of May 28, 2027 or next annual meeting Service-based vesting for the stock award

Key Terms

Grant, award, or other acquisition, Common Stock, annual meeting of stockholders

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders regulatory

"the Issuer's next annual meeting of stockholders following May 28, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fischer Seth H. Z.

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		79,873(1)	A	$0	141,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Esperion Therapeutics (ESPR) disclose in this Form 4 filing?

Esperion Therapeutics reported that director Seth H. Z. Fischer received a stock award of 79,873 shares of common stock. The grant is a compensation-related acquisition and not an open-market purchase, and it increased his directly held position to 141,023 shares.

How many Esperion (ESPR) shares were granted to director Seth H. Z. Fischer?

Seth H. Z. Fischer was granted 79,873 shares of Esperion common stock. These shares were awarded at a price of $0.00 per share as part of his director compensation and will vest in full based on the timing conditions described in the award.

When do the newly granted Esperion (ESPR) shares vest for the director?

The 79,873-share award vests in full on the earlier of May 28, 2027, or Esperion’s next annual meeting of stockholders following May 28, 2026. Until that vesting date is reached, the director does not fully own the award free of vesting conditions.

What is Seth H. Z. Fischer’s Esperion (ESPR) share ownership after this grant?

Following the grant, Seth H. Z. Fischer directly holds 141,023 shares of Esperion common stock. This total includes the newly awarded 79,873 shares, which are subject to vesting conditions tied to either a future date or the next annual stockholder meeting.

Was the Esperion (ESPR) director’s stock grant an open-market purchase or a compensation award?

The transaction was a compensation-related stock award, not an open-market purchase. It is coded as a “Grant, award, or other acquisition” with a transaction price of $0.00 per share, reflecting equity compensation for board service rather than a cash-funded buy.

Does this Esperion (ESPR) Form 4 indicate any stock sales by the director?

No, this Form 4 only reports an acquisition of shares through a grant. The transaction summary shows one acquisition and no dispositions or sales, indicating the filing relates solely to a director equity award and not to any selling activity.